Close
Nordic 9Nordic 9

Cormorant Asset Management (investor - Private Equity)

United States
See something wrong or missing? Let us know
Offices:Boston
Average round investment:83.95M USD
Average number per year:2.0
Distribution: 2024 (3)2021 (2)2020 (1)
Portfolio companies: Switzerland Numab TherapeuticsDenmark Orbis MedicinesBelgium Agomab See the entire list
Mostly invests in: Switzerland Switzerland (3) Health services (6)
See the entire list

Showing 3 of 6 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Cormorant Asset Management mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Cormorant Asset Management

Name Criteria
France Lauxera Capital Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, AI (big data)
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Northpond Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Polaris Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, AI (big data)
  • Similar business models: B2B
  • Common investees countries: Switzerland, Denmark
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Omega Funds
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, Belgium
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Bristol-Myers Squibb
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Finland NGP Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, AI (big data)
  • Similar business models: B2B
  • Common investees countries: Switzerland, Denmark
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
France Sanofi Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium, Denmark
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
United States Versant Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland, Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
South Korea Samsung Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, AI (big data)
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
United Kingdom IAG Silverstripe
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, AI (big data)
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Top